Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions and methods for preparing t cell compositions and uses thereof

A cell and cancer cell technology, applied in biochemical equipment and methods, drug combinations, animal cells, etc., can solve inherently complex and cumbersome problems

Pending Publication Date: 2022-01-14
BIONTECH US INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing strategies to obtain patient cells and to activate, expand and recover effective quantities of cells for ACT ex vivo are long-lasting, tedious and inherently complex processes and pose serious challenges

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for preparing t cell compositions and uses thereof
  • Compositions and methods for preparing t cell compositions and uses thereof
  • Compositions and methods for preparing t cell compositions and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0513] Example 1. Accurate Neostim Clinical Process

[0514] In this paper, late T cell therapy is provided, in which the pre-verified preserved subject cancer-specific antigen peptide pre-sensitive and responded T cells is applied to the subject. The method provided in this embodiment avoids lengthy sequencing, identifying and producing a subject-specific novel antigen peptide during the time of such evaluation and preparation of the subject, and the preparation of the preparation of the subject. The T cells having a subject specific TCR for cancer immunotherapy were produced. The advantage of this method is its rapid, targeted, and stable. like Figure 1A As shown in, patients who have been identified having cancer or tumors can be administered T cells, and the T cell is activated by peptide-managed peptide, which has a peptide-managed peptide having cancer known to identify. The selection of epitopes produced by the library of shared antigens, pre-verified collection. Process o...

Embodiment 2

[0515] Example 2. Production of target tumor cell antigen response T cells in vitro

[0516] Material:

[0517] AIM V medium (INVITROGEN)

[0518] Human flt3l, pre-clinical Cellgemx # 1415-050 Reserve 50NG / μL

[0519] TNF-α, preclinical Cellgenix # 1406-050, reserve 10 ng / μL

[0520] IL-1β, preclinical Cellgenix # 1411-050, reserve 10 ng / ul

[0521] PGE1 or Alprostadil-Cayman (from Czech Republic) Reserve 0.5μg / μL

[0522] R10 medium-rpmi 1640glutamax + 10% human serum + 1% PenStrep

[0523] 20 / 80 medium -18% AIM V + 72% rpmi 1640GLUTAMAX + 10% serum + 1% PenStrep

[0524] IL7 reserve 5NG L

[0525] IL15 reserve 5 ng / μL

[0526] program:

[0527] Step 1: In a 2 ml AIM V medium, 5 million PBMC (or target cells) is paved in each hole of 24-well plates with FLT3L.

[0528] Step 2: Peptide load and mature in AIMV

[0529] 1. Mix the target peptide library (except for peptide conditions) with PBMC (or target cells) in each well.

[0530] 2. Cost for 1 hour.

[0531] 3. Afte...

Embodiment 3

[0550] Example 3. Evaluation of antigen's presence

[0551] For a subset of the predicted antigen, the affinity of the new epitope and a new epitope having an HLA allele is determined for the HLA allele. Stability. Exemplary data of the subset of the RAS new antigen and GATA3 new antigen is shown Figure 4A and Figure 20 middle.

[0552] Exemplary Detailed Description of Scheme for Measuring Binding Prolycity of Peptide and I MHC has been announced (SETTE et al., Mol.immunol. 31 (11): 813-22, 1994). Briefly, the MHCI complex is prepared and combined to the radiolabeled reference peptide. The peptide was incubated with these complexs with different concentrations with these complexes and the remaining amount of the peptide bonded to MHCI was measured using a dimensional exclusion gel filtration. The lower the concentration of the test peptide required for the replacement of the radioactive labeled reference peptide indicates the more affinity of the test peptide to MHCI. Peptides o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
Login to View More

Abstract

Provided herein are compositions and methods for preparing T cell compositions and uses thereof, including methods for treating cancer in a subject in need thereof by administering T cells induced with peptides comprising an epitope sequence from a library of epitope sequences, wherein each epitope sequence in the library is matched to a protein encoded by an HLA allele and binds to a protein encoded by an HLA allele of the subject, is immunogenic according to an immunogenic assay, is presented by antigen presenting cells according to a mass spectrometry assay, and stimulates T cells to be cytotoxic according to a cytotoxicity assay.

Description

[0001] cross reference [0002] The present application claims the rights of US Provisional Application No. 62 / 827, 018, filed on March 30, 2019, which is incorporated herein by reference. Background technique [0003] Transduced immunotherapy or lateral cell therapy (ACT) using lymphocytes is transferred to a subject to treat disease. Continuous immunotherapy is to achieve its potential to treat many diseases, including cancer, infectious diseases, autoimmune diseases, inflammatory diseases and immunodeficiency. However, most (if not all) Continue immunotherapy require T cell activation and expansion steps to produce clinical effective treatment dose T cells. A conventional strategy for patient cells as well as cells in vitro activation, expanding and recovering effective quantity for ACT is a long-lasting and intrinsic process, and cause serious challenges. Therefore, there is still a need to develop a composition and method for expanding and inducing antigen-specific T cells ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00C07K14/705C12N5/00
CPCA61K2039/572A61P35/00A61K2039/876C12N5/0638C12N2501/25C12N2501/26C12N2501/2301C12N2501/2315A61K39/464464A61K39/4611C12N2502/1121C12N2501/2307C12N2501/02A61K39/464462A61K39/46446A61K39/464401C12N5/0637A61K39/464404A61K39/464416A61K39/464452
Inventor 罗伯特·安格维克拉姆·朱内贾理查德·盖诺
Owner BIONTECH US INC